Bulk Inquiry
BET BRD4 inhibitor compound II-25
- Optical Purity: Optically pure
- Soluble in 0.1N HCl(aq) and DMSO
- MF: C25H27N5O2
- MW: 429.51
Description
BET BRD4 inhibitor compound II-25 is a potent BRD4-BD1 inhibitor with an IC50 of 8 nM.
More Information
| Parent CAS No. | 1660117-38-3 |
|---|---|
| Chemical Name | (S)-2,4-Dimethyl-6-(1-(1-phenylethyl)-6-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)pyridazin-3(2H)-one |
| SMILES | C1CC(C2N=CC3N=C(C4=NN(C)C(=O)C(C)=C4)N([C@@H](C)C4C=CC=CC=4)C=3C=2)CCO1 |&1:19,r| |
| MFCD | N.A. |
| InChi | InChI=1S/C25H27N5O2/c1-16-13-21(28-29(3)25(16)31)24-27-22-15-26-20(19-9-11-32-12-10-19)14-23(22)30(24)17(2)18-7-5-4-6-8-18/h4-8,13-15,17,19H,9-12H2,1-3H3/t17-/m0/s1 |
| InChiKey | QNFGQQDKBYVNAS-KRWDZBQOSA-N |
| CID | 90647162 |
| Short Description | BET inhibitor |
References
- H Engelhardt et al. Pyridinones. WO2015022332A1.
- U Tontsch-Grunt et al. Synergistic activity of BET inhibitor BI 894999 with PLK inhibitor volasertib in AML in vitro and in vivo. Cancer Lett. 2018, 421, 112-120.
- D Gerlach et al. The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AML. Oncogene, 2018, 37, 2687–2701.
Related Products
| AXON ID | NAME | FROM PRICE |
|---|---|---|
| 1887 | PFI-1 |
From $82.50 |
| 1989 | (+)-JQ1 |
From $66.00 |
| 2245 | RVX 208 |
From $71.50 |
| 2530 | OTX 015 |
From $121.00 |
| 2594 | CPI 0610 |
From Inquiry |
| 2776 | CD161 |
From $154.00 |
| 3329 | ODM-207 |
From $154.00 |
| 3623 | SGC-SMARCA-BRDVIII |
From $99.00 |
| 3696 | ABBV-075 |
From $121.00 |
| 3716 | BMS-986158 |
From Inquiry |
| 3822 | (+)-JQ1 carboxylic acid |
From $121.00 |
| 3833 | AZD5153 HNT salt |
From Inquiry |
| 3860 | I-BET726 |
From Inquiry |
| 3873 | (-)-JQ-1 |
From $132.00 |
| 3921 | GSK046 |
From Inquiry |
| 3922 | dBET1 |
From Inquiry |
| 3944 | ARV-825 |
From Inquiry |
| 3956 | ABBV-744 |
From $132.00 |
| 4134 | I-BET762 |
From Inquiry |
| 4135 | I-BET151 |
From Inquiry |
